Mainz Biomed (NASDAQ:QUCY) Posts Earnings Results

Mainz Biomed (NASDAQ:QUCY) posted its earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.13 million for the quarter.

Mainz Biomed Stock Up 13.8%

Shares of Mainz Biomed stock traded up $0.06 during trading hours on Tuesday, hitting $0.47. 79,945 shares of the company’s stock traded hands, compared to its average volume of 668,516. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. Mainz Biomed has a twelve month low of $0.40 and a twelve month high of $4.43.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Maxim Group downgraded Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Weiss Ratings initiated coverage on shares of Mainz Biomed in a research report on Thursday, March 12th. They issued a “sell (e+)” rating for the company. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.